Hanyu Medical, a Chinese startup that develops heart valve interventional medical devices, has garnered 500 million yuan ($72 million) in its Series D round to promote the premarket clinical trials of what could be China’s first domestically developed mitral valve repair product.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in